Author:
HUDSON MARIE,THOMBS BRETT D.,STEELE RUSSELL,PANOPALIS PANTELIS,NEWTON EVAN,BARON MURRAY,
Abstract
Objective.Systemic sclerosis (SSc) affects multiple physical, psychological, and social domains and is associated with impaired health-related quality of life (HRQOL).We compared the HRQOL of SSc patients with individuals in the general population and patients with other common chronic diseases.Methods.HRQOL of SSc patients in the Canadian Scleroderma Research Group registry was measured using version 2 of the Medical Outcomes Trust Short Form-36 (SF-36). Results were compared to US general population norms and scores reported for patients with other common chronic diseases, namely heart disease, lung disease, hypertension, diabetes, and depression.Results.SF-36 scores were available for 504 SSc patients (86% women, mean age 56 yrs, mean disease duration since onset of first non-Raynaud’s manifestation of SSc 11 yrs). The greatest impairment in SF-36 subscale scores appeared to be in the physical functioning, general health, and role physical domains. SF-36 subscale and summary scores in SSc were significantly worse compared to US general population norms for women of similar ages, except for mental health and mental component summary score, which were not significantly different, and were generally comparable to or worse than the scores of patients with other common chronic conditions.Conclusion.HRQOL of patients with SSc is significantly impaired compared to that of the general population and is comparable to or worse than that of patients with other common chronic conditions.
Publisher
The Journal of Rheumatology
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference17 articles.
1. Seibold J . Scleroderma. In: Harris E Budd RC Firestein GS , editors. Kelley’s textbook of rheumatology. 7th ed. Philadelphia: Elsevier; 2005.
2. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time
3. Depression in patients with systemic sclerosis: A systematic review of the evidence
4. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6;Merkel;J Rheumatol,2003
5. The MOS 36-ltem Short-Form Health Survey (SF-36)
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献